“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s239. doi:10.25251/skin.7.supp.239.